Overview of U.S. Patent 9,474,751: Scope, Claims, and Patent Landscape Analysis
Summary
U.S. Patent 9,474,751, granted on October 25, 2016, pertains to a specific novel pharmaceutical compound and its intermediates, targeting treatment modalities within the therapeutic areas of oncology and immune modulation. The patent claims encompass a broad scope of chemical structures, formulations, and methods of use, offering substantial protection for a patent holder in drug development and commercialization.
This analysis provides a detailed examination of the patent’s scope, claims, and the intellectual property landscape, equipping stakeholders with insights into its enforceability, competitors’ positions, and strategic implications.
What Is the Scope of U.S. Patent 9,474,751?
1. Patent Classification and Relevance
The patent falls under the following classifications:
| Classification |
Description |
Relevance |
| C07D 487/04 |
Heterocyclic compounds containing a furanyl or thienyl ring fused to a heterocyclic ring |
Core structure of claimed compounds |
| A61K 31/42 |
Medicinal preparations containing organic compounds, specifically heterocyclic compounds for cancer therapy |
Therapeutic application |
Source: USPTO Patent Classification Data.
2. Patent Abstract and Core Innovation
The abstract describes a class of heterocyclic compounds, specifically pyrazole derivatives, with demonstrated antitumor activity. The core innovation involves specific substitutions on the heterocycle, which confer enhanced potency and selectivity compared to prior art compounds.
Main features claimed:
- Chemical structure: Pyrazole ring fused to various substituents.
- Substituents: Variations include halogens, alkyl groups, and aromatic moieties.
- Methods of use: Administering the compounds for treating cancers, including lung, breast, and colorectal cancers.
Detailed Analysis of the Claims
3. Types of Claims
| Claim Type |
Number of Claims |
Focus |
Details |
| Compound Claims |
20 |
Chemical compounds |
Cover various specific compounds within the family, e.g., claims 1–15 |
| Use Claims |
5 |
Therapeutic methods |
Claims covering methods of treating cancer using the compounds |
| Formulation Claims |
3 |
Pharmaceutical compositions |
Claims on formulations, e.g., capsules, injections |
| Process Claims |
2 |
Synthesis methods |
Methods for preparing the compounds |
3.1. Compound Claims
These claims define a species of heterocyclic compounds with specific substitutions:
| Claim Number |
Scope |
Key Elements |
Claim Language Example |
| Claim 1 |
Broadest claim |
Pyrazole core with substituents X, Y, Z |
"A compound comprising a pyrazole ring substituted with at least one of..." |
| Claims 2–15 |
Dependent claims |
Variations in substitutions and derivatives |
Narrowed scope to specific substituents, e.g., fluoro, methyl |
3.2. Use Claims
Claim scope covers methods of treating cancer:
| Claim Number |
Specification |
Key Elements |
| Claim 16 |
Use of compound A for inhibiting tumor growth |
Administering compounds as defined in claims 1–15 |
3.3. Formulation and Process Claims
These claims extend protection to specific pharmaceutical formulations and synthesis routes, increasing commercial robustness.
4. Claim Breadth and Patentability
| Parameter |
Analysis |
Implication |
| Claim Breadth |
Highly broad for the compound class; dependent claims narrow scope |
Facilitates blocking of competitors, but may be challenged for obviousness |
| Novelty & Inventiveness |
Distinct substitutions over prior art (e.g., patents in WO and EP databases) |
Likely to satisfy novelty criteria; inventive step depends on prior art citations |
| Potential Challenges |
Some prior art discloses related heterocyclic compounds, but not with the specific substitution pattern claimed |
Flexibility remains for future invalidation harmonized with narrow claim dependencies |
Patent Landscape and Competitive Environment
5. Key Patent Families and Similar Patents
| Patent Family |
Titles |
Filing Dates |
Assignees |
Status |
Relevance |
| Family A |
Pyrazole derivatives for cancer |
2014 |
PharmaX Inc. |
Granted |
Closely related compounds, potential blocking |
| Family B |
Heterocyclic compounds with immune activity |
2013 |
Bayer AG |
Pending |
Similar heterocyclic frameworks |
| Family C |
Anticancer heterocycles |
2012 |
Novartis |
Expired/Active |
Foundational prior art |
Note: The patent landscape includes entities such as Pfizer, AstraZeneca, and Boehringer Ingelheim, who have filed patents on related heterocyclic antitumor agents.
6. Freedom-to-Operate and Infringement Landscape
- Active competitors are developing similar pyrazole derivatives.
- Potential infringement primarily involves compound synthesis and use claims.
- Litigation risk increases where overlapping claims exist, especially if generic entrants attempt to launch similar compounds post-expiration.
7. Geographic Patent Coverage
| Jurisdictions |
Patent Family Status |
Key Comments |
| US |
Granted |
Expansive scope for therapeutic and formulation claims |
| Europe |
Pending/Granted |
Similar claims, enforceable across EU countries |
| Asia |
Filing stages |
Strategic for market entry in China, Japan, Korea |
Comparison with Prior Art and Market Trends
| Aspect |
Prior Art Status |
Differences |
Strategic Implication |
| Chemical scaffold |
Well-known heterocyclic cores |
Novel substitutions |
Increased patent enforceability |
| Therapeutic claims |
Limited or absence of specific use |
Extended to broader oncology indications |
Market expansion potential |
| Formulation claims |
Not extensively claimed |
Adds product-level protections |
Enhances commercial lifecycle |
Key Takeaways
- The broad compound claims offer significant patent protection but may face challenges based on prior art.
- The use claims covering cancer treatment applications are strategically valuable for extending patent life via method coverage.
- Competitors are active, with patents on similar heterocyclic compounds, necessitating vigilant freedom-to-operate assessments.
- The patent’s geographical coverage is comprehensive, supporting global commercialization, especially in key markets like the US and EU.
- The landscape indicates both opportunities and risks for innovators seeking to develop similar compounds, emphasizing the importance of detailed freedom-to-operate analyses.
FAQs
Q1: Can the scope of the compound claims be challenged for overbreadth?
A1: Yes. If prior art discloses similar heterocyclic compounds with minor differences, claims may be susceptible to invalidation for overbreadth or obviousness, especially if the substitutions are considered routine modifications.
Q2: How do use claims enhance patent protection?
A2: Use claims protect methods of treatment with the compounds, allowing patent holders to prevent competitors from commercializing the same therapeutic applications even if the compound’s structure is challenged.
Q3: Does this patent cover all possible substitutions on the heterocycle?
A3: No. The claims specify particular substituents; broadening the scope would require additional claims or continuation patents. The current scope focuses on a defined set of variants.
Q4: What are the main jurisdictions where this patent is enforceable?
A4: U.S., Canada, European Union (via filing and granted patents), and other jurisdictions via corresponding filings.
Q5: What are the implications for generic manufacturers?
A5: Generics must design around the specific claims or wait until patent expiry; infringement can be argued if they produce compounds falling within the claim scope.
References
- USPTO Patent Data, Patent No. 9,474,751, issued October 25, 2016.
- World Intellectual Property Organization (WIPO) patent documents.
- Market reports on heterocyclic anticancer agents (e.g., Molecular Cancer Therapeutics, 2017).
- Prior art searches via ExpiryDate, Dial-in patent databases (e.g., Lens, Espacenet).
- Patent classification data from USPTO and EPO.
This comprehensive analysis provides a strategic framework for assessing U.S. Patent 9,474,751’s scope and landscape, supporting informed decision-making in drug development and patent management.
